Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

4.82USD
24 Mar 2017
Change (% chg)

$0.23 (+5.01%)
Prev Close
$4.59
Open
$4.59
Day's High
$5.07
Day's Low
$4.58
Volume
121,077
Avg. Vol
210,355
52-wk High
$6.30
52-wk Low
$1.47

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals says appointed Steven Mento as acting principal financial officer on March 16
Tuesday, 21 Mar 2017 04:24pm EDT 

Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc - on March 16, board appointed Steven Mento as company's acting principal financial officer.  Full Article

Conatus Pharma qtrly loss per share $0.35
Wednesday, 15 Mar 2017 04:05pm EDT 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports 2016 financial results and program updates . Q4 revenue $800,000 . Q4 revenue view $1.7 million -- Thomson Reuters I/B/E/S .Qtrly loss per share $0.35.  Full Article

Conatus Pharmaceuticals says cfo Charles Cashion resigned
Friday, 17 Feb 2017 04:22pm EST 

Conatus Pharmaceuticals Inc :On February 16, 2017, Charles J. Cashion tendered his resignation as chief financial officer.  Full Article

Conatus Pharmaceuticals Inc qtrly loss per share $0.30
Wednesday, 3 Aug 2016 04:05pm EDT 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports second quarter 2016 financial results and program updates . Conatus pharmaceuticals inc qtrly loss per share $0.30 .Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

Conatus Pharmaceuticals Inc announces results from Multicenter Phase 2 Portal Hypertension Clinical Trial
Wednesday, 23 Sep 2015 04:01pm EDT 

Conatus Pharmaceuticals Inc:Exploratory Phase 2 Portal Hypertension (PH) clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, met the following primary endpoints.Portal hypertension, or elevated blood pressure in the major vein feeding into the liver, was confirmed by HVPG measurement >5 mmHg at baseline and measured again after treatment with 25 mg of emricasan orally twice daily for 28 days.  Full Article

Conatus Pharmaceuticals Inc enters into first amendment lease agreement - Form 8-K
Thursday, 4 Jun 2015 04:02pm EDT 

Conatus Pharmaceuticals Inc:Entered into first amendment to the lease agreement for its corporate office space with The Point Office Partners, LLC (first amendment).Under terms of first amendment, company will lease an additional 3,271 square feet for a total of approximately 13,225 square feet of office space from September 1, 2015 through September 30, 2020.Says monthly base rent will increase annually by approximately 3% from approximately $32,784 in 2015 to $39,268 in 2020.Company will be entitled to a one-time tenant improvement allowance of up to $65,420.  Full Article

Conatus Pharmaceuticals Inc completes public offering and full exercise of underwriters' option to purchase additional shares
Wednesday, 8 Apr 2015 04:01pm EDT 

Conatus Pharmaceuticals Inc:Completes previously announced underwritten public offering of 4,025,000 shares of its common stock, including 525,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares.Says all shares in the offering were sold by Conatus at a price to the public of $5.75 per share.Net proceeds to Conatus from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be about $21.4 mln.Conatus intends to use the net proceeds from the offering to fund clinical development of emricasan, including preparation for registration trials, and for working capital and other general corporate purposes.Stifel and Roth Capital Partners acted as book-running managers for the offering.  Full Article

More From Around the Web

BRIEF-Conatus Pharmaceuticals says appointed Steven Mento as acting principal financial officer on March 16

* Conatus Pharmaceuticals Inc - on March 16, board appointed Steven Mento as company's acting principal financial officer Source text: (http://bit.ly/2mN9zSd) Further company coverage: